PrintThe goal of this examination is to provide the learner with a means to determine individual knowledge gaps in the treatment of patients with opioid use disorder (OUD) and pain. Read more
MAT in the OTP Setting: Integrating the Three Approved Medications (Methadone, Buprenorphine, ER Naltrexone) – Revised
Kelly J. Clark, MD, MBA | Chair, OTP Workgroup, American Society of Addiction Medicine
This module will give the clinician an understanding of the opportunities and challenges of integrating into the Opioid Treatment Program (OTP) environment treatment with all three FDA approved medications – methadone, buprenorphine (SL and buccal), and ER Naltrexone. The special characteristics of OTPs, and its place in the continuum of care, provide a unique environment for these pharmacotherapies. This module will discuss these, as well as clinical and operational issues involved in developing an integrated approach.
Read more
Managing Acute & Chronic Pain with Opioid Analgesics in Patients on Medication Assisted Treatment (MAT) – Revised
Daniel P. Alford, MD, MPH, FACP, FASAM | Associate Professor of Medicine, Assistant Dean, Continuing Medical Education, Director, Clinical Addiction Research and Education Unit, Boston University School of Medicine & Boston Medical Center
A variety of medications have been deemed effective in contributing to the positive outcome of patients being treated for opiate dependence. This module considers the advantages and disadvantages of these medications in the treatment of patients of varying characteristics. Read more
Methadone: Its Role in Opioid Addiction Treatment vs. Pain Management – Revised
Yngvild Olsen, MD, MPH | American Society of Addiction Medicine; Kenneth B. Stoller, MD | American Association for the Treatment of Opioid Dependence
This module focuses on the role of methadone in opioid addiction treatment compared to when it is used for pain management. The module describes key pharmacological differences of methadone for the two indications, including methadone dosing and monitoring considerations. The module reviews the history of methadone and the unique regulations that apply to the use of methadone in treating opioid addiction compared to its use in treating pain. The module describes the epidemiologic impact of methadone on morbidity and mortality related to opioid use disorder compared to that related to pain. Finally, the module provides suggestions on what information patients should receive if methadone is part of a treatment regimen for opioid use disorder or pain. Read more
Talk about opioid use disorder with your patients: A clinical practice simulation
The Talk About Opioids app is a clinical practice simulation in which you will learn and practice effective techniques to identify patients with opioid use disorders (OUD) and discuss symptoms and appropriate treatment options. Read more
Module 1: Understanding Substance Use Disorders
Brian Fuehrlein, MD, PhD | Director, Psychiatric Emergency Room, VA, Connecticut and Assistant Professor of Psychiatry, Yale University
Provides a basic introduction of the concepts of the disease model of addiction and the role of the reward system. Using neuroscience concepts as a foundation, clinical manifestations of the disease of addiction are then discussed in the form of case-based presentations. Read more
Module 2: Alcohol and Drug Use Disorders
Brian Fuehrlein, MD, PhD | Director, Psychiatric Emergency Room, VA, Connecticut and Assistant Professor of Psychiatry, Yale University
Outlines the basic concepts of alcohol and drug use disorders. Standard drink sizes, screening for alcohol use disorders and an introduction to alcohol withdrawal management are discussed. A basic overview of the major drug use disorders are then discussed in a clinically-relevant manner. Read more
Module 3: The Opioid Epidemic
Brian Fuehrlein, MD, PhD | Director, Psychiatric Emergency Room, VA, Connecticut and Assistant Professor of Psychiatry, Yale University
Provides an overview of the history of opioid use with an overview of contributing factors to the current epidemic. Using clinical cases, opioid use disorder is then discussed in detail. Finally, there is a discussion of harm reduction approaches and treatment options. Read more
Module 4: Medication and Behavioral Treatment of Substance Use Disorders
Brian Fuehrlein, MD, PhD | Director, Psychiatric Emergency Room, VA, Connecticut and Assistant Professor of Psychiatry, Yale University
Introduces evidence-based clinical practices of pharmacotherapy and behavioral treatments for substance use disorders. Off label medications and psychosocial support programs are also discussed. Read more
Developing a Behavioral Treatment Protocol in Conjunction with MAT (Revised)
Kenneth M. Carpenter, Ph.D. | Columbia University Medical Center, New York, NY, Center for Motivation and Change, New York, NY;
Nicole Kosanke, Ph.D. | Center for Motivation and Change, New York, NY
This module provides an overview of four principles that may play an important role in facilitating behavior change among substance dependent individuals. The combination of psychosocial and medication assisted treatment protocols can provide an additive benefit to individuals striving to alter their substance use. Read more
